Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is strategically positioned to capitalize on its proprietary technologies aimed at neurodegenerative diseases, particularly with its promising pipeline which includes advanced candidates such as ACI-7104.056, a PD active immunotherapy that has demonstrated a significant 20-fold increase in antibodies targeting pathogenic variants of aSyn. Additionally, the potential positive outcomes from the NLRP3 program and the upcoming EVOKE trial could enhance investor interest, especially as the treatment landscape increasingly favors safer, easily administered agents that effectively identify patients and maximize treatment efficacy.

Bears say

AC Immune SA reported a net operating loss of CHF16.2 million for the quarter, reflecting ongoing financial challenges as a clinical-stage biopharmaceutical company. The firm is subject to significant risks typical of the biotechnology industry, including the possibility of adverse clinical trial outcomes, regulatory hurdles, and heightened complexity in commercial markets that are sensitive to pricing. These factors contribute to a negative outlook for the company as it navigates the uncertain landscape of developing therapeutics for neurodegenerative diseases.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.